产品中心 药物靶点和Fc受体 药物靶点

所有图片(1/1)

Siglec-6/CD327 Fc Chimera Protein, Human

价格 1,200.00 供应商现货 : 3-5个工作日
货号 UA010027
规格
数量
收藏 分享

关联产品推荐

产品介绍 评论(0)

产品规格
  • 物种

    Human
  • Accession

    AAH35359.2
  • 表达序列

    Gln16-Val320, with C-terminal Human IgG Fc
  • 表达宿主

    HEK293
  • 分子量

    75-95 kDa(Reducing)

  • 纯度

    >95%, by SDS-PAGE under reducing conditions
  • 内毒素含量

    <0.1EU/μg
  • 标记

    Unconjugated
  • 标签

    Human Fc Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, pH7.4
  • 溶解方法

    Reconstitute at less than 1 mg/mL according to the size in ultrapure water after rapid centrifugation .

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.
背景介绍
  • Siglec-6 also called CD327, one of the Sialic acid-binding immunoglobulin-like lectins (Siglecs) and type-1 transmembrane protein. Siglec-6 is predominantly expressed by mast cells, B cells, and a minor AS-type dendritic cell subset. Siglec-6 is an immune-inhibitory CD33-related Siglec and strongly binds to sialylated Tn-structures. As an exception, all Siglecs recognize the carboxyl group of sialic acid, but only Siglec-6 does not require the glycerol side-chain for binding. In cancer, Siglec-6 was recently found to be upregulated in circulating and urinary CD8+ T-cell of non–muscle-invasive bladder cancer patients, wherein a high level of Siglec-6 was associated with advanced bladder cancer. Additionally, Siglec-6 is prevalently expressed on acute myeloid leukemia blasts and transformed B cells in chronic lymphocytic leukemia. As Siglec-6 mRNA and protein are not expressed in hematopoietic stem cells, they are novel targets for CAR-T cell immunotherapy in chronic lymphocytic leukemia.

  • 电泳

    • Siglec-6/CD327 Fc Chimera, Human,2μg >95%, by SDS-PAGE under reducing conditions.

评论(0)